Take a trial of UK to unlock this pageFind out more


« All RNS

GLAXOSMITHKLINE | Transaction In Own Shares | RNS

RNS Number : 5996X
GlaxoSmithKline PLC
16 February 2012
 



GlaxoSmithKline plc (the "Company") announces that in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 5 May 2011 it purchased 420,000 of its Ordinary shares of 25 pence each ("shares") on 16 February 2012.

 

The highest price paid per share was 1,426.5 pence per share.

The lowest price paid per share was 1,404.0 pence per share.

The Company intends to hold these shares in Treasury.

 

The Company holds 502,862,927 of its shares in Treasury, representing 9.05% of the total issued share capital of the Company. 

 

Including shares which have been purchased but not yet settled, the Company holds 504,192,927 of its shares in Treasury, representing 9.98% of the total voting rights in the Company.

 

The Company has 5,050,618,069 shares in issue (excluding shares held in Treasury). This number represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Services Authority's Disclosure and Transparency Rules.

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer to purchase or subscribe for securities in any jurisdiction and is in conformity with the Financial Services Authority's Disclosure and Transparency Rules.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
POSLLFVDFTIRLIF



GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSK's Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSK's Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China. more »

Share Price (Full)
1319.5p
Change
1.9%
Mkt Cap (£m)
63,021
P/E (fwd)
15.8
Yield (fwd)
6.6


 
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder